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Focused Ultrasound Surgery for
Obsessive-Compulsive Disorders:
Potential for use as a Novel Ablative
Surgical Technique
Kyung Won Chang, Hyun Ho Jung and Jin Woo Chang*
Department of Neurosurgery & Brain Research Institute, Yonsei University College of Medicine, Seoul, South Korea
Surgical treatment for psychiatric disorders, such as obsessive-compulsive disorder
(OCD) and depression, using ablative techniques, such as cingulotomy and capsulotomy,
have historically been controversial for a number of scientific, social, and ethical reasons.
Recently, with the elucidation of anatomical and neurochemical substrates of brain
function in healthy controls and patients with such disorders using various functional
neuroimaging techniques, these criticisms are becoming less valid. Furthermore, by using
new techniques, such as deep brain stimulation (DBS), and identifying more precise
targets, beneficial effects and the lack of serious complications have been demonstrated
in patients with psychiatric disorders. However, DBS also has many disadvantages.
Currently, magnetic resonance-guided focused ultrasound surgery (MRgFUS) is used as
a minimal-invasive surgical method for generating precisely placed focal thermal lesions
in the brain. Here, we review surgical techniques and their potential complications, along
with anterior limb of the internal capsule (ALIC) capsulotomy by radiofrequency lesioning
and gamma knife radiosurgery, for the treatment of OCD and depression. We also
discuss the limitations and technical issues related to ALIC capsulotomy with MRgFUS
for medically refractory OCD and depression. Through this review we hope MRgFUS
could be considered as a new treatment choice for refractory OCD.
Keywords: deep brain stimulation, gamma knife surgery, magnetic resonance-guided focused ultrasound,
obsessive-compulsive disorder, psychosurgery
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a mental disorder characterized by time-consuming,
distressing obsessions and/or compulsions (1). Obsessions are repetitive and persistent thoughts,
images, impulses, or urges that are intrusive and unwanted and are commonly associated with
anxiety (1). Compulsions are repetitive behaviors or mental acts that the individual feels driven
to perform, according to strict rules, in response to an obsession or to achieve a sense of
“completeness.” It is often accompanied by avoidance behavior (1).
Most patients experience a continuous symptom course, although there is a waxing and waning
symptom pattern in up to 25% (2). However, symptom progression can be highly influenced by
treatment. Individuals with OCD often have a poor quality of life, similar to individuals with
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schizophrenia (3). The burden of personal and socio-economic
costs associated with OCD is also considerable (4). Nevertheless,
the condition is often unrecognized, particularly because
symptoms are often internally experienced rather than externally
expressed, and patients may be unwilling to reveal thoughts or
behaviors that they perceive as shameful or embarrassing (5).
Consequently, the mean time from OCD symptom onset to
initial pharmacological treatment is nearly 8 years (6). Among
patients who receive clinical attention, <40% receive OCD-
specific therapy and <10% receive evidence-based treatment (7).
The initial treatment for OCD involves pharmacological
treatment or cognitive-behavioral therapy (CBT) (1, 5, 8).
Selective serotonin-reuptake inhibitors (SSRIs) are the first-line
of pharmacological treatment for OCD, with proven efficacy
in reducing OCD symptoms and tolerability demonstrated in
multiple trials (9). However, approximately half of OCD patients
treated with first-line treatment fail to show a complete response
(10). Insufficient response after CBT or SSRI monotherapy can
also be resolved by combination therapy (5, 8). For treatment-
refractory OCD, after failure of SSRI or combination therapy,
alternative approaches could be considered. Neurosurgical
techniques, focused on the lesioning of specific components
of the neural circuits associated with OCD, have been used
for decades to treat patients with severe, treatment-refractory
symptoms (11–13). In this reviews, we provide an overview of the
history of surgery for psychiatric disorders and discuss the latest
surgical options for psychiatric disorders, with a focus on OCD.
To our knowledge there are few review regarding MRgFUS as a
treatment option for psychiatric disorders.
BRIEF HISTORY OF PSYCHIATRIC
NEUROSURGERY
Surgery for psychiatric disorders includes techniques involving
neuroablation and neuromodulation, such as stimulation
techniques. Psychiatric neurosurgery has a long history of
controversy for various scientific, social, and ethical reasons.
Throughout the 1800s, new knowledge regarding functional
neuroanatomy and neurophysiology sparked an interest in
psychiatric neurosurgery (14). In 1819, Franz Joseph Gall
published his thesis on phrenology, suggesting that the brain
has distinct functional areas (15). Although the concept of
phrenology was defective and was eventually discounted, the
idea of neurological functions having an anatomical correlation
was expanded on by the seminal work on the localization of
language function by Paul Broca and Carl Wernicke, followed
by further research by Gustav Fritsch, Eduard Hitzig, and
David Ferrier on the localization of the motor cortex (16).
These findings inspired interest in psychiatric neurosurgery.
In 1889, Gottlieb Burckhardt presented his operative findings
and outcomes at the Berlin Medical Congress (17). In six
patients with various psychiatric disorders, he conducted
selective removal of the left frontotemporal cerebral cortex. In
three of these cases, Burckhardt claimed to achieve success in
treatment, but his eccentric research was deeply criticized by
the international medical community when he published his
surgical results in 1891, leading to discontinuation of the project.
Research on and practice of psychiatric neurosurgery stagnated
until 1935, when a primate model study by John Fulton and
Carlyle Jacobsen described the frontal lobe’s role in short term
memory, anxiety, and aggression (14). This study encouraged
Egas Moniz and Almeida Lima to perform the first prefrontal
leucotomies in 20 psychiatric patients with schizophrenia,
bipolar disorder, and anxiety disorders (18). Walter Freeman
and James Watts modified the technique and began to perform
modified lobotomies in 1936 (14, 17, 19), which became popular
worldwide. By 1949, an estimated 10,000 lobotomies had been
performed in the US and Europe. Moniz won the 1949 Nobel
Prize for medicine for the discovery of the role of prefrontal
leucotomy in the treatment of certain psychoses (17).
Nevertheless, eventually both professional and public opinion
turned against lobotomy, as the procedure was regarded as
unethical and unscientific. Additionally, the associatedmorbidity
and mortality, the so called “post-leucotomy syndrome,” became
more evident (14, 20). To reduce the morbidity and mortality,
a more selective approach was considered, and improvements
were attained with advances in stereotactic neurosurgery.
In 1949, Talairach announced the use of a stereotactic
frame to coagulate the frontothalamic fibers in the ALIC
selectively, at the 4th International Congress of Neurology
in Paris (17). Thereafter, stereotactic psychiatric neurosurgery
rapidly replaced prefrontal lobotomy and was applied for
various psychiatric disorders (21): cingulotomy for addiction,
bipolar disorder, depression, OCD, schizoaffective disorder, and
schizophrenia; anterior capsulotomy for general anxiety disorder
and OCD; subcaudate tractotomy for depression, OCD, and
schizophrenia; anterior callosotomy for schizoaffective disorder
and schizophrenia; amygdalotomy for aggressive behavior
associated with mental impairment; thalamotomy for Tourette
syndrome and hypothalamotomy for addiction, aggression, and
sexual disorders.
In the 1950s and 1960s, the use of psychiatric neurosurgery
declined, and the number of patients requiring stereotactic
psychiatric neurosurgery was markedly reduced (22, 23). This
can be ascribed to multiple factors, such as social attitudes and
ethical problems, as well as the introduction of psychoactive
drugs, such as chlorpromazine, reserpine, lithium, haloperidol,
imipramine, and diazepam. The development and approval of
other antipsychotics and antidepressants soon followed, and
there was evidence that medical therapy was more effective, safer,
and cheaper than psychiatric neurosurgery (14).
Although there was controversy surrounding the evolution of
psychiatric neurosurgery, it was instrumental in the development
of modern standards of research and ethics, with the passing of
the National Research Act of 1974 and subsequent publication
of the Belmont Report (14). The 1977 US National Commission
Report on Psychiatric Neurosurgery claims “The Commission
affirms that the use of psychosurgery for any purpose other than
to provide treatment to individual patients would be inappropriate
and should be prohibited. Accordingly, the Commission is
recommending safeguards that should prevent the performance of
psychosurgery for purposes of social or institutional control or other
such misuse.” (24).
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Various neuroablative surgeries have been performed for OCD.
Each surgery is named for its target, such as capsulotomy
targeting the internal capsule, cingulotomy targeting the
anterior cingulate cortex, and subcaudate tractotomy targeting
the subcaudate white matter. Limbic leucotomy involves a
combination of the latter two procedures (5, 12, 21). The
concept underlying ablative surgery for OCD is based on the
pathological hyperactivity and dysfunctional connectivity in the
limbic cortico-striato-thalamo-cortical (CSTC) loop (25).
Currently, the ablative methods used most commonly are
radiofrequency and radiosurgical ablation, as well as the
novel magnetic resonance-guided focused ultrasound surgery
(MRgFUS) (21, 26–30). Approximately 30–60% of patients with
intractable OCD may experience significantly reduced OCD
symptoms post-operatively (1). However, only gamma ventral
capsulotomy has been studied in a double-blind, sham-controlled
randomized trial (31). Using the response criteria [a 35%
reduction in the baseline Yale–Brown Obsessive Compulsive
Scale (Y-BOCS) score plus a Clinical Global Impression change
score of 1 or 2], the primary outcome measure did not reach
statistical significance after 12 months, although the Y-BOCS
score reduction over that same follow-up period was significantly
greater in the active treatment group. At the end of the follow-
up period (54 months), 7 of 12 (58%) patients who underwent
radiosurgery were deemed responders.
Cingulotomy
The anterior cingulate cortex is a region in the medial prefrontal
cortex that surrounds the rostral corpus callosum. This region
seems to have emotional and cognitive functions. Both functional
roles make the anterior cingulate cortex a theoretically ideal focus
for therapeutic intervention in psychiatric disorders in which
these processes are impaired (25).
After Egas Moniz announced his first prefrontal leucotomy
in 1936, thousands of patients with mental disorders underwent
frontal lobar surgery until the 1950s (32), with modifications
introduced by Walter Freeman and James Watts (19). However,
because of the lack of anatomical precision of frontal leucotomy
and the emergence of side effects, more restricted surgeries,
such as frontal topectomy or undercutting under direct
visualization or by electrocoagulation, were developed (33).
After the stimulation of Brodmann area 24 in monkeys showed
autonomic changes in emotional expression and a widespread
cortical suppressor effect (34), bilateral removal of the anterior
part of the cingular gyrus, i.e., anterior cingulotomy, was
performed by Whitty et al. (35). Among the 24 patients in
their series, four OCDpatients showed significant improvements.
Subsequently, in 1962, Foltz and White reported that stereotaxic
cingulotomy in patients with intractable pain also improved
their anxiety or depression (36). With these impressive results,
Ballantine et al. performed bilateral stereotaxic cingulotomy for
57 patients with mental disorders (32) in 1967, and showed
variable improvements in 30 patients. In 1972, Laitinen et al.
used a stereotaxic frame for cingulotomy (37), and in 1990,
radiofrequency was first used by Hassenbusch et al. (38).
According to Ballantine et al.’s large study in 1987 (39),
more than 400 OCD patients underwent bilateral stereotactic
cingulotomy. The reported overall success rate was 30–40%, with
no other major side effects, but some minor complications were
identified, such as persistent headache, nightmares, decreased
libido, weight gain, and urinary incontinence. Adverse effects
after cingulotomy have been reported as transient to mild
symptoms, such as urinary symptoms (14%), as well as
permanent to serious symptoms, such as epilepsy or cognitive
changes (5.2%) (40).
In our institute’s series regarding cingulotomy for OCD (28,
41), 17 patients had a Y-BOCS score of 35.0± 3.86 preoperatively
and showed a mean improvement of 48% over the baseline score
after a follow-up period of at least 2 years. A neuropsychological
examination was performed in all of our patients to investigate
whether there were any differences in cognitive function at 24
months after cingulotomy. No significant adverse effects were
observed after the surgery. In a recent long-term study with a
5-year mean follow-up period in 64 patients, Sheth et al. (42)
showed a 47% rate of full response (more than 35% improvement
in the Y-BOCS score).
Capsulotomy
Disruption of the ALIC is thought to yield efficacious or
therapeutic relief in some psychiatric disorders, and some
studies have demonstrated orbitofrontal cortex and subgenual
cingulate projections leading to the medial thalamic nucleus.
In 1949, Talairach first introduced the technique of anterior
capsulotomy to disconnect fibers from the orbitofrontal cortex
leading to the limbic system that pass through the ALIC for
patients with psychiatric disorders (17). In the 1950s, Leksell
and Talairach modernized anterior capsulotomy (43). In 1953,
the first radiosurgical capsulotomy was performed with 300-
kV X-rays (44). Lippitz et al. reported 22 cases of bilateral
thermo-capsulotomy from 1976 to 1989, with a median follow-
up period of 8.4 years; beneficial results were seen in 47% of
cases (45). Bilateral thermo-capsulotomy results from a recent
large study were reported by numerous studies. The rate of
improvement in Y-BOCS scores was 43.3% according to Oliver
et al. (n = 10) (46), 80.9% according to Liu et al. (n =
35) (47), and 31.4% according to D’Astous et al. (n = 19)
(48). The adverse effects after capsulotomy were reported as
transient to mild in 56.2% of patients and as permanent to
serious in 21.4% of patients in another study (40). Leksell
introduced capsulotomy via gamma knife radiosurgery in 1955
(44). Improvements after gamma knife anterior capsulotomy
were observed in 55–70% of patients. However, anatomical target
localization, dose, and collimator selection varied among reports
(44). Rück et al. in their series, compared thermo-capsulotomy
and gamma capsulotomy (49) and found some side effects,
such as apathy, incontinence, seizure, and executive dysfunction;
they also reported that a very high radiation dose or multiple
procedures should be avoided. Additionally, larger targets using
an 8-mm collimator showed adverse radiation effects (50).
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Gamma capsulotomy has a risk of adverse radiation effects,
such as radiation necrosis or brain edema or cyst formation
(49). Worldwide, more than 240 cases of gamma capsulotomy
were performed, and if the maximal dose was reduced below
180Gy, the number of adverse effects decreased (51). In a recent
double-blind, randomized controlled trial by Lopes et al., 58.3%
(7/12) of cases were deemed responders after gamma ventral
capsulotomy (31). Recently, in a large study of capsulotomy by
Rasmussen et al. (52) 31 out of 55 patients had an improvement
in the Y-BOCS score in a primary measure, and over 35%
improvement in 3-year follow-up period. Patients had significant
improvements in depression, anxiety, quality of life, and global
functioning without significant acute adverse effects, only 5%
patients developed radio-necrotic cysts in long term follow-
up. As the capsulotomy procedure have advanced, the adverse
events have decreased significantly, with a remaining favorable
treatment response of∼50∼ 66% of patients which were treated
at experienced centers (53). The reduction in the severity of
OCD may also result from improved efficacy of pharmacological
and psychological treatments that work synergistically with
capsulotomy as well as direct modulation of the OCD neural
pathways (53).
Limbic Leukotomy
Limbic leucotomy is a combination of anterior cingulotomy
and capsulotomy or subcaudate tractotomy. Kelly et al. (54)
performed limbic leucotomies starting in the 1970s, with
proven efficacy for mood disorders and OCD. Depending on
the clinical symptoms, limbic leucotomy can be performed
as a one-stage procedure (55), in which frontothalamic
white matter tracts of the basal medial frontal lobes are
lesioned, along with lesioning in anterior cingulate cortex.
Alternatively, it can be performed in a two-stage procedure
involving initial anterior cingulotomy, followed by subcaudate
tractotomy (56). In a 7-year prospective study of patients
with intractable bipolar disorder, one-stage limbic leucotomy
yielded a significant reduction in depressive symptoms but
not in manic symptoms (57). One group who performed a
two-stage procedure showed a 73% symptom improvement
rate in patients with OCD and intractable major depressive
disorder who did not initially respond to anterior cingulotomy
alone (56). The side effects of limbic leucotomy appear to be
transient and to resolve spontaneously; they include transient
hallucinations, amnesia, and mania (42). In particular, however,
abulia appears to develop at a higher rate following limbic





DBS is an adjustable, reversible, and non-destructive procedure
that has been proven to be safe for treating movement
disorders. With DBS, surgically implanted electrodes deliver
controlled electrical pulses to targeted areas of the brain,
which activate adjacent neural circuits (58). The settings of
the stimulation can be changed, and the electrodes can be
removed from the brain. Compared to ablative neurosurgery,
DBS has the advantages of being reversible and adjustable.
Thus, there has been a trend for replacement of ablation
techniques by DBS.
Significant advances in neuroscience and neuroimaging have
resulted in the discovery of some circuits in the brain (59),
and the application of DBS has increased with the greater
understanding of the pathophysiology of psychiatric disorders.
DBS is reserved for highly refractory OCD cases, i.e., < ∼1%
of patients (60). Approximately 30–50% of patients with severe
refractory OCD respond to these alternative treatments (13, 61).
DBS has been attempted using various targets. Most studies
on DBS have targeted striatal areas, including the ALIC, ventral
capsule (VC), ventral striatum (VS), nucleus accumbens or
the ventral caudate nucleus, subthalamic nucleus, and inferior
thalamic peduncle (1, 13, 62, 63). Preliminary studies have
also described the potential benefit of non-striatal targets,
such as the superolateral branch of the medial forebrain
bundle (64).
DBS was initially applied in the ALIC by Nuttin et al. (65),
and reported DBS results for OCD: the mean preoperative
Y-BOCS score of 32.3 ± 3.9 decreased to 19.8 ± 8.0 post-
operatively, and the stimulation effect was maintained for at least
21 months after DBS. The effect of DBS in the internal capsule
was limited and required high power, resulting in high battery
consumption. Thus, the DBS target was gradually shifted more
posteriorly where the anatomical sites were close to the VS, VC,
nucleus accumbens, inferior thalamic peduncle, and bed nucleus
of the stria terminalis (66, 67). Greenberg et al. (68) targeted
the VC/VS where more compact fibers of the CSTC circuit
course, slightly posterior to the target of standard capsulotomy.
Additionally, the effects of DBS were more pronounced with
posterior stimulation. The more posteriorly the electrode
was positioned, the less energy (voltage and pulse width)
was needed.
The nucleus accumbens plays a major role in modulating the
CSTC circuit. Sturm et al. (62) designed a double-blind sham-
controlled crossover study with unilateral DBS for the nucleus
accumbens. Five of 10 patients showed reduction of more than
25% over the baseline Y-BOCS score, and one patient showed
a reduction of > 35% at 1 year post-operation. Another study
on bilateral nucleus accumbens DBS in 16 patients by Denys
et al. (69) reported 47 and 52% reductions from the baseline
Y-BOCS score after 12 and 21 months, respectively. Bilateral
DBS in the inferior thalamic peduncle and in the limbic part
of the subthalamic nucleus has also been reported, but the
patients included were somewhat diverse and the sample size was
small (67, 70).
Surgical risks still exist, and both lesioning and DBS pose
a risk of hemorrhage, seizures, and infection. Although
the risk of intracerebral hemorrhage is inevitable, the
occurrence rates are low (1–2% in large studies), irrespective
of the symptoms (71). Additionally, the implantable
pulse generator should be replaced when the battery
is depleted.
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Several experimental studies on focused ultrasound lesioning
were conducted in the 1950s (72, 73). Owing to skull anatomy
and the characteristics of ultrasound, focused ultrasound was
only applied during craniotomy until the 1990s. The skull acts
as a barrier and is a major obstacle against the penetration
of ultrasound for making a focal lesion in the brain, and the
heat from energy absorption can damage the scalp, bone, and
adjacent brain parenchyma (74). The development of the phased
array transducer and the introduction of MR thermometry made
it possible to use transcranial MRgFUS as an ablative method
(75). Unlike stereotactic radiofrequency procedures, which are
irreversible, MRgFUS lesioning allows modification during the
procedure since the thermal area can be monitored in real-
time.
Transcranial MRgFUS is a minimally invasive and real-time
monitoring procedure that has advantages over surgical
techniques, such as radiosurgery, and other lesioning
procedures (26). Intermittently examining the MR image
or using MR thermometry during the sonication can
confirm or predict the lesioning, and no ionizing radiation
is involved. In addition, its precision and the feasibility of
real-time monitoring during the procedure can minimize
procedure-related complications (76). In addition, there
are no other concerns about hardware implantation or
replacement, or surgical morbidity, as with DBS. MRgFUS
is a potentially more viable and cost-effective alternative to
radiofrequency capsulotomy (26). Recently, MRgFUS has
been widely applied for the treatment of various movement
disorders (essential tremors, etc.), but there have been few
studies involving psychiatric disorders. In our institute,
MRgFUS for OCD has been done since our first study in
2013 (27).
Patient Selection and Inclusion Criteria
Patients who were diagnosed as treatment-refractory OCD
were selected. All patients failed to respond to more than
three SSRIs, including clomipramine, and more than one
antipsychotic drug augmentation strategy (one or more SSRIs
and one or more antipsychotics) and had OCD symptoms
with psychosocial impairment for at least 5-years. Experienced
psychiatrists conducted psychiatric interviews for diagnoses and
assessment of symptoms or psychosocial functions. The inclusion
criteria of the patients are: (1) a primary OCD diagnosis
according to the Structured Clinical Interview of the Diagnostic
and Statistical Manual of Mental Disorders; (2) at least a 3-
year history of OCD symptoms with psychosocial dysfunction
(determined by a Global Assessment of Functioning Scale, score
650); (3) a minimum score of 28 on the Yale–Brown Obsessive-
Compulsive Scale (Y-BOCS); and (4) treatment refractory status,
that is, non-responsive to pharmacological treatment (more than
two types of serotonin reuptake inhibitors at the maximum
tolerated dose for more than 12 weeks) and cognitive-behavioral
therapy [a minimum of 20 sessions of primarily therapist-guided
Exposure and Response Prevention (ERP)]. Previous medication
(SSRIs or antipsychotics) were kept unchanged for at least 30
days before MRgFUS capsulotomy, and the regimen and dosage
were maintained until the final assessment from the follow-
up visit.
MRgFUS Capsulotomy: Procedures &
Targeting
MRgFUS capsulotomy was performed using a 3-T MR system
(GE Medical Systems, Milwaukee, WI, USA) and the ExAblate
4,000 system (InSightec, Haifa, Israel) which features a 30-cm
diameter, hemispherical, 1,024 element phased-array transducer
operating at 650 kHz. The patient’s scalp is completely shaved
and after the fixation of the Cosman–Roberts–Wells stereotactic
frame, the patient is positioned to the ExAblate 4,000 system.
A presonication MRI is performed and the images are fused
with computed tomography, and other MR sequences are also
evaluated to determine the target coordinates. The bilateral
ALIC is targeted from the location 7-mm anterior to the
anterior margin of the anterior commissure in the level of
AC–PC (Anterior Commissure—Posterior Commissure) plane,
extending 2–3mm along the internal capsule in the coronal
view. Several subthreshold heatings with low-power sonications
of 10 s durations were applied to induce peak temperatures of
40–42◦C. This low power sonication procedure is for safety
which allows us to visualize the exact position and size of the
thermal spot and to review the overall safety profile of the
applied sonication parameters. After confirming the exact target,
high-power sonication was then applied in a repetitive process
guided by MRI and MR thermometry, with gradual increase in
acoustic power and energy to achieve a peak temperature of 51–
56◦C in the target region for more than 3 s. By adjusting the
target coordinates, the goal is to create an ∼10-mm elliptical
lesion in each side of the bilateral ALIC. During the procedure,
particularly during cooling time, the patient is asked questions
and examined by a neurosurgeon and a psychiatrist to observe
whether there are notable physical or psychological changes.
The patient is fully awake during the whole procedure and
is monitored as an inpatient for 24 h after the procedure
(Figure 1).
In study of treatment-refractory OCD in 11 patients who
underwent MRgFUS in our institute (30), the Y-BOCS score
decreased significantly over the 24-month follow-up period
(mean ± standard deviation, 34.4 ± 2.3 at baseline v. 21.3
± 6.2 at 24 months, p < 0.001). In addition, scores on
the Hamilton Rating Scales for Depression (HAM-D) and
Anxiety (HAM-A) also significantly decreased from baseline
over the 24-month period (HAM-D, 19.0 ± 5.3 v. 7.6 ± 5.3,
p < 0.001; HAM-A, 22.4 ± 5.9 v. 7.9 ± 3.9, p < 0.001).
The Global Assessment of Functioning (GAF) scores improved
significantly (35.8 ± 4.9 at baseline v. 56.0 ± 10.3 at 24
months, p < 0.001). Other neuropsychological function test
scores, such as Wechsler Adult Intelligence Scale-Korean version
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FIGURE 1 | One-week post-operative MR image of a patient with MRgFUS Capsulotomy.
scores, Memory Quotient scores, and Digit Span test-forward
scores, were significantly improved, while other test scores, such
as the Controlled Oral Word Association test scores, Stroop
test scores, and Digit Span test-backward scores, remained
unchanged. Compared to the pre-sonication condition, high-
resolution fluorodeoxyglucose positron emission tomography
of the eight patients showed significantly decreased uptake
in the orbitofrontal cortex (p < 0.001). The side effects of
MRgFUS included headache and vestibular symptoms, but
these were mild and temporary. Thus, these findings showed
that bilateral thermal lesioning of the ALIC using MRgFUS
may improve obsessive-compulsive, depressive, and anxiety
symptoms in patients with treatment-refractory OCD, without
serious side effects.
In our very recent study (77), we successfully performed
bilateral thermal capsulotomy with MRgFUS in four patients
with treatment-resistant depression (TRD). All patients
underwent MRgFUS without serious side effects. During the
12-month follow-up period, all four patients experienced
reduced symptoms and improved functional scores: the
Beck Depression Inventory and Hamilton Depression Scale
(HAM-D) scores decreased by 61.2 and 83.0%, respectively,
and the GAF total score improved by more than 50%. Our
results were consistent with those of TRD patients who
underwent conventional radiofrequency capsulotomy, although
we observed faster improvement in our patients. Three of
the four patients experienced a faster decrease in symptoms
within 1 week of MRgFUS, which may be due to post-
procedure anxiety relief. In addition, all participants were
able to continue their daily activities from the day after the
procedure, without complications. These results suggest the
possibility that capsulotomy by MRgFUS can also improve
various psychiatric disorders.
In a recent study by Davidson et al. (78). MRgFUS
capsulotomy was performed in 12 patients (six patients with
OCD and six patients with MDD) without serious clinical or
radiographic adverse events. For OCD, a 35% reduction in the
Yale-Brown Obsessive-Compulsive Scale and for MDD, a 50%
reduction in the 17-item Hamilton Depression Rating Scale
was observed.
However, as research is still insufficient, in order
not to repeat the mistakes of the previous history of
psychiatric neurosurgery, it is important to conduct
research on MRgFUS capsulotomy only in institutions
with teams of well-experienced functional neurosurgeons
and psychiatrists.
To date, the application of MRgFUS for numerous brain
targets for treating psychiatric disorders has been limited (29, 76)
in patients with a low skull-density ratio (which represents a
skull that is difficult to penetrate by ultrasound) and with lateral
targets (on which it is difficult to focus ultrasound). Nevertheless,
ongoing technical development may eventually overcome
these limitations.
CONCLUSION
Among the currently available surgical techniques, MRgFUS is
emerging as a promising ablative surgical method. Further larger
cohort studies are required to compare the surgical methods
in future.
Frontiers in Psychiatry | www.frontiersin.org 6 April 2021 | Volume 12 | Article 640832
Chang et al. MRgFUS for OCD
AUTHOR CONTRIBUTIONS
KC wrote the paper. HJ and JC provided the idea and reviewed
the paper. All authors contributed to the article and approved the
submitted version.
FUNDING
This study was supported by a grant of the Korea Health
Technology R&D Project through the Korea Health
Industry Development Institute (KHIDI), funded by the
Ministry of Health and Welfare, Republic of Korea (Grant
No. HI19C0060).
ACKNOWLEDGMENTS
This is a short text to acknowledge the contributions of specific
colleagues, institutions, or agencies that aided the efforts of
the authors.
REFERENCES
1. Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG,
et al. Obsessive–compulsive disorder. Nat Rev Disease Primers. (2019) 5:52.
doi: 10.1038/s41572-019-0102-3
2. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The
brown longitudinal obsessive compulsive study: clinical features and
symptoms of the sample at intake. J Clin Psychiatry. (2006) 67:703–
11. doi: 10.4088/JCP.v67n0503
3. Subramaniam M, Soh P, Vaingankar JA, Picco L, Chong SA. Quality of life in
obsessive-compulsive disorder: impact of the disorder and of treatment. CNS
Drugs. (2013) 27:367–83. doi: 10.1007/s40263-013-0056-z
4. Ramos-Cerqueira AT, Torres AR, Torresan RC, Negreiros AP, Vitorino
CN. Emotional burden in caregivers of patients with obsessive-compulsive
disorder. Depress Anxiety. (2008) 25:1020–7. doi: 10.1002/da.20431
5. Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder.
JAMA. (2017) 317:1358–67. doi: 10.1001/jama.2017.2200
6. Dell’Osso B, Camuri G, Benatti B, Buoli M, Altamura AC. Differences in
latency to first pharmacological treatment (duration of untreated illness) in
anxiety disorders: a study on patients with panic disorder, generalized anxiety
disorder and obsessive-compulsive disorder. Early Interv Psychiatry. (2013)
7:374–80. doi: 10.1111/eip.12016
7. Torres AR, Prince MJ, Bebbington PE, Bhugra DK, Brugha TS, Farrell M,
et al. Treatment seeking by individuals with obsessive-compulsive disorder
from the british psychiatric morbidity survey of (2000). Psychiatr Serv. (2007)
58:977–82. doi: 10.1176/ps.2007.58.7.977
8. Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA,
Salkovskis P, et al. Pharmacological and psychotherapeutic interventions
for management of obsessive-compulsive disorder in adults: a systematic
review and network meta-analysis. Lancet Psychiatry. (2016) 3:730–
9. doi: 10.1016/S2215-0366(16)30069-4
9. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective
serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive
compulsive disorder (OCD). Cochrane Database Syst Rev. (2008)
2008:CD001765. doi: 10.1002/14651858.CD001765.pub3
10. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive
disorder: methodological issues, operational definitions and
therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry. (2006)
30:400–12. doi: 10.1016/j.pnpbp.2005.11.028
11. Nuttin B, Wu H, Mayberg H, Hariz M, Gabriels L, Galert T, et al. Consensus
on guidelines for stereotactic neurosurgery for psychiatric disorders. J Neurol
Neurosurg Psychiatry. (2014) 85:1003–8. doi: 10.1136/jnnp-2013-306580
12. Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-based
neurotherapeutics: stereotactic ablation and deep brain stimulation for
OCD. Neuropsychopharmacology. (2010) 35:317–36. doi: 10.1038/npp.
2009.128
13. Alonso P, Cuadras D, Gabriels L, Denys D, Goodman W, Greenberg BD,
et al. Deep brain stimulation for obsessive-compulsive disorder: a meta-
analysis of treatment outcome and predictors of response. PLoS ONE. (2015)
10:e0133591. doi: 10.1371/journal.pone.0133591
14. Staudt MD, Herring EZ, Gao K, Miller JP, Sweet JA. Evolution
in the treatment of psychiatric disorders: from psychosurgery to
psychopharmacology to neuromodulation. Front Neurosci. (2019)
13:108. doi: 10.3389/fnins.2019.00108
15. Simpson D. Phrenology and the neurosciences: contributions
of F. J. Gall and J. G. Spurzheim. ANZ J Surg. (2005) 75:475–
82. doi: 10.1111/j.1445-2197.2005.03426.x
16. Robison RA, Taghva A, Liu CY, Apuzzo ML. Surgery of the mind, mood,
and conscious state: an idea in evolution. World Neurosurg. (2013) 80:S2–
26. doi: 10.1016/j.wneu.2013.08.002
17. Luigjes J, de Kwaasteniet BP, de Koning PP, Oudijn MS, van den Munckhof P,
Schuurman PR, et al. Surgery for psychiatric disorders. World Neurosurgery.
(2013) 80:S31.e17-S31.e28. doi: 10.1016/j.wneu.2012.03.009
18. Moniz E. Prefrontal leucotomy in the treatment of mental disorders 1937. Am
J Psychiatry. (1994). 151(6 Suppl):236-9. doi: 10.1176/ajp.151.6.236
19. Gross D, Schafer G. Egas Moniz (1874-1955) and the “invention” of
modern psychosurgery: a historical and ethical reanalysis under special
consideration of Portuguese original sources. Neurosurg Focus. (2011)
30:E8. doi: 10.3171/2010.10.FOCUS10214
20. Heller AC, Amar AP, Liu CY, Apuzzo ML. Surgery of the mind and mood:
a mosaic of issues in time and evolution. Neurosurgery. (2008) 62(6 Suppl
3):921–40. doi: 10.1227/01.NEU.0000333761.30877.8D
21. Leiphart JW, Valone FH 3rd. Stereotactic lesions for the
treatment of psychiatric disorders. J Neurosurg. (2010) 113:1204–
11. doi: 10.3171/2010.5.JNS091277
22. Feldman RP, Goodrich JT. Psychosurgery: a historical overview.Neurosurgery.
(2001) 48:647–57; discussion 57–9. doi: 10.1097/00006123-200103000-00041
23. Ballantine HT, Jr. Historical overview of psychosurgery and
its problematic. Acta Neurochir Suppl (Wien). (1988) 44:125–
8. doi: 10.1007/978-3-7091-9005-0_25
24. Levine RJ. Recommendations of the national commission for the protection
of human subjects of biomedical and behavioral research: impact on research
in pharmacology. Introduction Fed Proc. (1977) 36:2341–3.
25. Sinha S, McGovern RA, Mikell CB, Banks GP, Sheth SA. Ablative limbic
system surgery: review and future directions. Curr Behav Neurosci Rep. (2015)
2:49–59. doi: 10.1007/s40473-015-0038-1
26. Kumar KK, Bhati MT, Ravikumar VK, Ghanouni P, Stein SC,
Halpern CH. MR-guided focused ultrasound versus radiofrequency
capsulotomy for treatment-refractory obsessive-compulsive disorder:
a cost-effectiveness threshold analysis. Front Neurosci. (2019)
13:66. doi: 10.3389/fnins.2019.00066
27. Jung HH, Kim SJ, Roh D, Chang JG, Chang WS, Kweon EJ, et al.
Bilateral thermal capsulotomy with MR-guided focused ultrasound for
patients with treatment-refractory obsessive-compulsive disorder: a proof-
of-concept study. Mol Psychiatry. (2014) 20:1205–11. doi: 10.1038/mp.
2014.154
28. Jung HH, Kim C-H, Chang JH, Park YG, Chung SS, Chang JW. Bilateral
anterior cingulotomy for refractory obsessive-compulsive disorder: long-
term follow-up results. Stereotactic Functional Neurosurgery. (2006) 84:184–
9. doi: 10.1159/000095031
29. Jung HH, Chang WS, Kim SJ, Kim C-H, Chang JW. The potential
usefulness of magnetic resonance guided focused ultrasound for
obsessive compulsive disorders. J Korean Neurosurg Soc. (2018)
61:427–33. doi: 10.3340/jkns.2017.0505.004
30. Kim SJ, Roh D, Jung HH, Chang WS, Kim C-H, Chang JW. A study of
novel bilateral thermal capsulotomy with focused ultrasound for treatment-
refractory obsessive–compulsive disorder: 2-year follow-up. J Psychiatry
Neurosci. (2018) 43:327–37. doi: 10.1503/jpn.170188
Frontiers in Psychiatry | www.frontiersin.org 7 April 2021 | Volume 12 | Article 640832
Chang et al. MRgFUS for OCD
31. Lopes AC, Greenberg BD, Canteras MM, Batistuzzo MC, Hoexter MQ,
Gentil AF, et al. Gamma ventral capsulotomy for obsessive-compulsive
disorder: a randomized clinical trial. JAMA Psychiatry. (2014) 71:1066–
76. doi: 10.1001/jamapsychiatry.2014.1193
32. Ballantine HT Jr, Cassidy WL, Flanagan NB, Marino R Jr. Stereotaxic anterior
cingulotomy for neuropsychiatric illness and intractable pain. J Neurosurg.
(1967) 26:488–95. doi: 10.3171/jns.1967.26.5.0488
33. Scoville WB. Selective cortical undercutting as a means of modifying and
studying frontal lobe function in man; preliminary report of 43 operative
cases. J Neurosurg. (1949) 6:65–73. doi: 10.3171/jns.1949.6.1.0065
34. Dunsmore RH, Lennox MA. Stimulation and strychninization
of supracallosal anterior cingulate gyrus. J Neurophysiol. (1950)
13:207–14. doi: 10.1152/jn.1950.13.3.207
35. Whitty CW, Duffield JE, Tov PM, Cairns H. Anterior cingulectomy
in the treatment of mental disease. Lancet. (1952) 1:475–
81. doi: 10.1016/S0140-6736(52)90051-2
36. Foltz EL, White LE Jr. Pain “relief” by frontal cingulumotomy. J Neurosurg.
(1962) 19:89–100. doi: 10.3171/jns.1962.19.2.0089
37. Laitinen L, Toivakka E, Vilkki I. [Rostral cingulotomy for mental disorders
(electrophysiologic, psychological and clinical findings)]. Vopr Neirokhir.
(1973) 37:23–30.
38. Hassenbusch SJ, Pillay PK, Barnett GH. Radiofrequency
cingulotomy for intractable cancer pain using stereotaxis guided
by magnetic resonance imaging. Neurosurgery. (1990) 27:220–
3. doi: 10.1227/00006123-199008000-00008
39. Ballantine HT Jr, Bouckoms AJ, Thomas EK, Giriunas IE. Treatment of
psychiatric illness by stereotactic cingulotomy. Biol Psychiatry. (1987) 22:807–
19. doi: 10.1016/0006-3223(87)90080-1
40. Brown LT, Mikell CB, Youngerman BE, Zhang Y, McKhann GM, 2nd,
Sheth SA. Dorsal anterior cingulotomy and anterior capsulotomy for severe,
refractory obsessive-compulsive disorder: a systematic review of observational
studies. J Neurosurg. (2016) 124:77–89. doi: 10.3171/2015.1.JNS14681
41. Kim CH, Chang JW, Koo MS, Kim JW, Suh HS, Park IH, et al. Anterior
cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr
Scand. (2003) 107:283–90. doi: 10.1034/j.1600-0447.2003.00087.x
42. Sheth SA, Neal J, Tangherlini F,MianMK,Gentil A, Cosgrove GR, et al. Limbic
system surgery for treatment-refractory obsessive-compulsive disorder: a
prospective long-term follow-up of 64 patients. J Neurosurg. (2013) 118:491–
7. doi: 10.3171/2012.11.JNS12389
43. Leksell L. Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry. (1983)
46:797–803. doi: 10.1136/jnnp.46.9.797
44. Leveque M, Carron R, Regis J. Radiosurgery for the treatment of
psychiatric disorders: a review. World Neurosurg. (2013) 80:S32 e1–
9. doi: 10.1016/j.wneu.2013.07.004
45. Lippitz B, Mindus P, Meyerson BA, Kihlstrom L, Lindquist C. Obsessive
compulsive disorder and the right hemisphere: topographic analysis of
lesions after anterior capsulotomy performed with thermocoagulation. Acta
Neurochir Suppl. (1997) 68:61–3. doi: 10.1007/978-3-7091-6513-3_11
46. Oliver B, Gascon J, Aparicio A, Ayats E, Rodriguez R, Maestro De Leon
JL, et al. Bilateral anterior capsulotomy for refractory obsessive-compulsive
disorders. Stereotact Funct Neurosurg. (2003) 81:90–5. doi: 10.1159/0000
75110
47. Liu K, Zhang H, Liu C, Guan Y, Lang L, Cheng Y, et al. Stereotactic
treatment of refractory obsessive compulsive disorder by bilateral
capsulotomy with 3 years follow-up. J Clin Neurosci. (2008)
15:622–9. doi: 10.1016/j.jocn.2007.07.086
48. D’Astous M, Cottin S, Roy M, Picard C, Cantin L. Bilateral
stereotactic anterior capsulotomy for obsessive-compulsive disorder:
long-term follow-up. J Neurol Neurosurg Psychiatry. (2013)
84:1208–13. doi: 10.1136/jnnp-2012-303826
49. Ruck C, Karlsson A, Steele JD, Edman G, Meyerson BA, Ericson
K, et al. Capsulotomy for obsessive-compulsive disorder: long-
term follow-up of 25 patients. Arch Gen Psychiatry. (2008)
65:914–21. doi: 10.1001/archpsyc.65.8.914
50. Kihlstrom L, Hindmarsh T, Lax I, Lippitz B, Mindus P, Lindquist
C. Radiosurgical lesions in the normal human brain 17 years after
gamma knife capsulotomy. Neurosurgery. (1997) 41:396–401; discussion
−2. doi: 10.1097/00006123-199708000-00011
51. Kondziolka D, Flickinger JC, Hudak R. Results following
gamma knife radiosurgical anterior capsulotomies for obsessive
compulsive disorder. Neurosurgery. (2011) 68:28–32; discussion
23–3. doi: 10.1227/NEU.0b013e3181fc5c8b
52. Rasmussen SA, Noren G, Greenberg BD, Marsland R, McLaughlin
NC, Malloy PJ, et al. Gamma ventral capsulotomy in intractable
obsessive-compulsive disorder. Biol Psychiatry. (2018) 84:355–
64. doi: 10.1016/j.biopsych.2017.11.034
53. Miguel EC, Lopes AC,McLaughlin NCR, Noren G, Gentil AF, Hamani C, et al.
Evolution of gamma knife capsulotomy for intractable obsessive-compulsive
disorder.Mol Psychiatry. (2019) 24:218–40. doi: 10.1038/s41380-018-0054-0
54. Kelly D, Richardson A, Mitchell-Heggs N. Stereotactic limbic leucotomy:
neurophysiological aspects and operative technique. Br J Psychiatry. (1973)
123:133–40. doi: 10.1192/bjp.123.2.133
55. Mashour GA, Walker EE, Martuza RL. Psychosurgery: past,
present, and future. Brain Res Brain Res Rev. (2005) 48:409–
19. doi: 10.1016/j.brainresrev.2004.09.002
56. Bourne SK, Sheth SA, Neal J, Strong C, Mian MK, Cosgrove
GR, et al. Beneficial effect of subsequent lesion procedures after
nonresponse to initial cingulotomy for severe, treatment-refractory
obsessive-compulsive disorder. Neurosurgery. (2013) 72:196–202;
discussion doi: 10.1227/NEU.0b013e31827b9c7c
57. Cho DY, Lee WY, Chen CC. Limbic leukotomy for intractable major affective
disorders: a 7-year follow-up study using nine comprehensive psychiatric
test evaluations. J Clin Neurosci. (2008) 15:138–42. doi: 10.1016/j.jocn.
2006.10.017
58. Lujan JL, Chaturvedi A,McIntyre CC. Tracking themechanisms of deep brain
stimulation for neuropsychiatric disorders. Front Biosci. (2008) 13:5892–
904. doi: 10.2741/3124
59. Bear RE, Fitzgerald P, Rosenfeld JV, Bittar RG. Neurosurgery for obsessive-
compulsive disorder: contemporary approaches. J Clin Neurosci. (2010) 17:1–
5. doi: 10.1016/j.jocn.2009.02.043
60. Garnaat SL, Greenberg BD, Sibrava NJ, Goodman WK, Mancebo MC, Eisen
JL, et al. Who qualifies for deep brain stimulation for OCD? Data from a
naturalistic clinical sample. J Neuropsychiatry Clin Neurosci. (2014) 26:81–
6. doi: 10.1176/appi.neuropsych.12090226
61. Hamani C, Pilitsis J, Rughani AI, Rosenow JM, Patil PG, Slavin KS,
et al. Deep brain stimulation for obsessive-compulsive disorder: systematic
review and evidence-based guideline sponsored by the American Society
for Stereotactic and Functional Neurosurgery and the Congress of
Neurological Surgeons (CNS) and endorsed by the CNS and American
Association of Neurological Surgeons. Neurosurgery. (2014) 75:327–33; quiz
33. doi: 10.1227/NEU.0000000000000499
62. Sturm V, Lenartz D, Koulousakis A, Treuer H, Herholz K, Klein JC, et al.
The nucleus accumbens: a target for deep brain stimulation in obsessive-
compulsive- and anxiety-disorders. J Chem Neuroanat. (2003) 26:293–
9. doi: 10.1016/j.jchemneu.2003.09.003
63. Chang WS, Roh D, Kim CH, Chang JW. Combined bilateral anterior
cingulotomy and ventral capsule/ventral striatum deep brain stimulation for
refractory obsessive-compulsive disorder withmajor depression: do combined
procedures have a long-term benefit? Restor Neurol Neurosci. (2013) 31:723–
32. doi: 10.3233/RNN-120290
64. Coenen VA, Schlaepfer TE, Goll P, Reinacher PC, Voderholzer U, Tebartz
van Elst L, et al. The medial forebrain bundle as a target for deep brain
stimulation for obsessive-compulsive disorder. CNS Spectr. (2017) 22:282–
9. doi: 10.1017/S1092852916000286
65. Nuttin BJ, Gabriels L, van Kuyck K, Cosyns P. Electrical stimulation of the
anterior limbs of the internal capsules in patients with severe obsessive-
compulsive disorder: anecdotal reports.Neurosurg Clin N Am. (2003) 14:267–
74. doi: 10.1016/S1042-3680(02)00117-1
66. van Kuyck K, Brak K, Das J, Rizopoulos D, Nuttin B. Comparative study
of the effects of electrical stimulation in the nucleus accumbens, the
mediodorsal thalamic nucleus and the bed nucleus of the stria terminalis
in rats with schedule-induced polydipsia. Brain Res. (2008) 1201:93–
9. doi: 10.1016/j.brainres.2008.01.043
67. Jimenez-Ponce F, Velasco-Campos F, Castro-Farfan G, Nicolini H, Velasco
AL, Salin-Pascual R, et al. Preliminary study in patients with obsessive-
compulsive disorder treated with electrical stimulation in the inferior
Frontiers in Psychiatry | www.frontiersin.org 8 April 2021 | Volume 12 | Article 640832
Chang et al. MRgFUS for OCD
thalamic peduncle. Neurosurgery. (2009) 65(6 Suppl):203–9; discussion
9. doi: 10.1227/01.NEU.0000345938.39199.90
68. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF,
et al. Three-year outcomes in deep brain stimulation for highly resistant
obsessive-compulsive disorder. Neuropsychopharmacology. (2006) 31:2384–
93. doi: 10.1038/sj.npp.1301165
69. Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F,
Westenberg H, et al. Deep brain stimulation of the nucleus accumbens
for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry.
(2010) 67:1061–8. doi: 10.1001/archgenpsychiatry.2010.122
70. Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, et al.
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N
Engl J Med. (2008) 359:2121–34. doi: 10.1056/NEJMoa0708514
71. Videnovic A, Metman LV. Deep brain stimulation for Parkinson’s disease:
prevalence of adverse events and need for standardized reporting.MovDisord.
(2008) 23:343–9. doi: 10.1002/mds.21753
72. Fry WJ, Barnard JW, Fry FJ, Brennan JF. Ultrasonically produced
localized selective lesions in the central nervous system. Am J Phys Med.
(1955) 34:413–23.
73. Fry WJ. Intense ultrasound in investigations of the
central nervous system. Adv Biol Med Phys. (1958) 6:281–
348. doi: 10.1016/B978-1-4832-3112-9.50012-8
74. Chang KW, Park YS, Chang JW. Skull factors affecting outcomes of magnetic
resonance-guided focused ultrasound for patients with essential tremor.
Yonsei Med J. (2019) 60:768–73. doi: 10.3349/ymj.2019.60.8.768
75. Kyriakou A, Neufeld E, Werner B, Paulides MM, Szekely G, Kuster N.
A review of numerical and experimental compensation techniques for
skull-induced phase aberrations in transcranial focused ultrasound. Int J
Hyperthermia. (2014) 30:36–46. doi: 10.3109/02656736.2013.861519
76. Giordano M, Caccavella VM, Zaed I, Foglia Manzillo L, Montano N, Olivi A,
et al. Comparison between deep brain stimulation and magnetic resonance-
guided focused ultrasound in the treatment of essential tremor: a systematic
review and pooled analysis of functional outcomes. J Neurol Neurosurg
Psychiatry. (2020) 91:1270–8. doi: 10.1136/jnnp-2020-323216
77. Chang Jg, Jung HH, Kim SJ, Chang WS, Jung NY, Kim CH, et al.
Bilateral thermal capsulotomy with magnetic resonance-guided focused
ultrasound for patients with treatment-resistant depression: a proof-
of-concept study. Bipolar Disorders. (2020) 22:771–4. doi: 10.1111/
bdi.12964
78. Davidson B, Hamani C, Huang Y, Jones RM, Meng Y, Giacobbe P,
et al. Magnetic resonance-guided focused ultrasound capsulotomy
for treatment-resistant psychiatric disorders. Operative Neurosurgery.
(2020). doi: 10.1093/ons/opaa240. [Epub ahead of print].
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Chang, Jung and Chang. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Psychiatry | www.frontiersin.org 9 April 2021 | Volume 12 | Article 640832
